Table 2 Study outcomes
Outcome | Placebo (N = 15) | Na ascorbate (N = 15) | Difference (95% CI) |
|---|---|---|---|
Mean (95% CI) | Mean (95% CI) | ||
Primary outcome | |||
Total urine output at 24 h (ml) | 2056 (1520–2593) | 2948 (2181–3715) | 891.5 (− 2.1 to 1785.2) || |
| Â | Median (IQR) | Median (IQR) | Difference (BCa 95% CI) |
|---|---|---|---|
Secondary outcomes | |||
Alive and vasopressor-free hours 7 days | 151 (124–160) | 148 (136–162) | 3 (− 26 to 19) |
Alive and ICU-free days at day 28 | 23 (21–26) | 21 (17–25) | 2 (− 3 to 6) |
Hospital length of stay (day) | 11 (8–24) | 15 (8–29) | − 4 (− 23 to 8) |
Alive and ventilator-free hours at 28 days | 637 (563–659) | 605 (482–652) | 32 (− 103 to 250) |
Peak serum creatinine at day 7 (µmol/L) | 111 (89–134) | 96 (69–195) | 15 (− 79 to 59) |
Time from randomization to start of study drug (hours) | 0.58 (0.38–0.87) | 0.92 (0.71–1.21) | − 0.34 (− 0.75 to 0) |
Time from sepsis diagnosis to start of study drug (hours) | 14 (10, 21) | 11 (6–14) | 3 (− 4 to 10) |
Incidence of hypernatremia | 0 (0) | 1 (7) | – |
| Â | No. of patients (%) | No. of patients (%) | Difference (95% CI) |
|---|---|---|---|
Death before ICU discharge by day 28 | 1 (7) | 3 (20) | − 13 (− 30 to 4) |
Death before discharge home by day 28 | 1 (7) | 3 (20) | − 13 (− 30 to 4) |
Death from any cause at any location by day 28 | 1 (7) | 3 (20) | − 13 (− 30 to 4) |
Renal replacement therapy | 0 (0) | 2 (13) | – |